188 related articles for article (PubMed ID: 32325917)
1. Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1.
Yilmaz O; Daly A; Pinto A; Ashmore C; Evans S; Gupte G; Santra S; Preece MA; Mckiernan P; Kitchen S; Ayhan NY; MacDonald A
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325917
[TBL] [Abstract][Full Text] [Related]
2. Casein Glycomacropeptide: An Alternative Protein Substitute in Tyrosinemia Type I.
Daly A; Evans S; Pinto A; Ashmore C; MacDonald A
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579102
[TBL] [Abstract][Full Text] [Related]
3. Hepatorenal Tyrosinaemia: Impact of a Simplified Diet on Metabolic Control and Clinical Outcome.
Bärhold F; Meyer U; Neugebauer AK; Thimm EM; Lier D; Rosenbaum-Fabian S; Och U; Fekete A; Möslinger D; Rohde C; Beblo S; Hochuli M; Bogovic N; Korpel V; Dahl SV; Mayorandan S; Fischer A; Freisinger P; Dokoupil K; Heddrich-Ellerbrok M; Jörg-Streller M; van Teeffelen-Heithoff A; Lahl J; Das AM
Nutrients; 2020 Dec; 13(1):. PubMed ID: 33396520
[No Abstract] [Full Text] [Related]
4. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
[TBL] [Abstract][Full Text] [Related]
6. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
Joshi SN; Venugopalan P
Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
[TBL] [Abstract][Full Text] [Related]
7. Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia.
Wilson CJ; Van Wyk KG; Leonard JV; Clayton PT
J Inherit Metab Dis; 2000 Nov; 23(7):677-83. PubMed ID: 11117429
[TBL] [Abstract][Full Text] [Related]
8. Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria.
Scala I; Concolino D; Nastasi A; Esposito G; Crisci D; Sestito S; Ferraro S; Albano L; Ruoppolo M; Parenti G; Strisciuglio P
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836270
[TBL] [Abstract][Full Text] [Related]
9. Over Restriction of Dietary Protein Allowance: The Importance of Ongoing Reassessment of Natural Protein Tolerance in Phenylketonuria.
Pinto A; Almeida MF; MacDonald A; Ramos PC; Rocha S; Guimas A; Ribeiro R; Martins E; Bandeira A; Jackson R; van Spronsen F; Payne A; Rocha JC
Nutrients; 2019 Apr; 11(5):. PubMed ID: 31052331
[TBL] [Abstract][Full Text] [Related]
10. Treatment adherence in tyrosinemia type 1 patients.
González-Lamuño D; Sánchez-Pintos P; Andrade F; Couce ML; Aldámiz-Echevarría L
Orphanet J Rare Dis; 2021 Jun; 16(1):256. PubMed ID: 34082789
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
[TBL] [Abstract][Full Text] [Related]
12. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
[TBL] [Abstract][Full Text] [Related]
13. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
14. Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long-Term Study.
Burlina AP; Cazzorla C; Massa P; Polo G; Loro C; Gueraldi D; Burlina AB
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31640267
[TBL] [Abstract][Full Text] [Related]
15. Outcome of children with hereditary tyrosinaemia following newborn screening.
McKiernan PJ; Preece MA; Chakrapani A
Arch Dis Child; 2015 Aug; 100(8):738-41. PubMed ID: 25564536
[TBL] [Abstract][Full Text] [Related]
16. Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.
Wisse RP; Wittebol-Post D; Visser G; van der Lelij A
BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23203167
[TBL] [Abstract][Full Text] [Related]
17. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Gissen P; Preece MA; Willshaw HA; McKiernan PJ
J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
[No Abstract] [Full Text] [Related]
19. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.
van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110
[TBL] [Abstract][Full Text] [Related]
20. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.
Schlump JU; Perot C; Ketteler K; Schiff M; Mayatepek E; Wendel U; Spiekerkoetter U
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S223-5. PubMed ID: 18500574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
